Hexadellin A | 121135-00-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Hexadellin A
• 英文别名: (5R,6S)-N-[3-[4-(2-aminoethyl)-2,6-dibromophenoxy]propyl]-7,9-dibromo-6-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,7,9-triene-3-carboxamide
• CAS: 121135-00-0
• 化学式: C₂₁H₂₃Br₄N₃O₅
• 分子量: 717.0
• InChiKey: DJOILUOUAWXGIG-CTNGQTDRSA-N

物化性质

• 密度：
  1.99±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Hexadellin A 、 乙酸酐 生成 [(5R,6S)-3-[3-[4-(2-acetamidoethyl)-2,6-dibromophenoxy]propylcarbamoyl]-7,9-dibromo-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,7,9-trien-6-yl] acetate
  参考文献：
  名称：

  MORRIS, SANDRA A.;ANDERSEN, RAYMOND J., CAN. J. CHEM., 67,(1989) N, C. 677-681

  摘要：

  DOI：

文献信息

• Marine Compounds with Calcium Channel Blocking Properties for the Treatment of Cognitive or Neurodegenerative Diseases
  申请人：Gil Ana Martinez

  公开号：US20080039513A1

  公开（公告）日：2008-02-14

  The invention provides compounds having a spiro heterocyclic unit connected through a linker of a certain length to another spiro cycle, an imidazole ring or an amide group. Some of these compounds have been obtained from Aplysinia cavernicola and a mixture of Aplysina fulva and Oceanapia . The compounds exhibit VDCC blocker activity; some also show acetylcholinesterase and butyrylcholinesterase inhibition activities. Therefore they are useful in the treatment of cognitive and neurodegenerative disorders, such as brain ischemia, stroke, cognitive disorders as senile dementia, cerebrovascular dementia, mild recognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimers's disease or condition, or prion disease as Creutzfeld-Jakob disease or Gerstmann-Straussler-Scheinker disease.
• [EN] MARINE COMPOUNDS WITH CALCIUM CHANNEL BLOCKING PROPERTIES FOR THE TREATMENT OF COGNITIVE OR NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSES MARINS POSSEDANT DES PROPRIETES BLOQUANT LES CANAUX CALCIQUES, DESTINES AU TRAITEMENT DE MALADIES COGNITIVES OU NEURODEGENERATIVES
  申请人：NEUROPHARMA SA

  公开号：WO2005123073A1

  公开（公告）日：2005-12-29

  The invention provides compounds having a spiro heterocyclic unit connected through a linker of a certain length to another spiro cycle, an imidazole ring or an amide group. Some of these compounds have been obtained from Aplysinia cavernicola and a mixture of Aplysina fulva and Oceanapia. The compounds exhibit VDCC blocker activity; some also show acetylcholinesterase and butyrylcholinesterase inhibition activities. Therefore they are useful in the treatment of cognitive and neurodegenerative disorders, such as brain ischemia, stroke, cognitive disorders as senile dementia, cerebrovascular dementia, mild recognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimers's disease or condition, or prion disease as Creutzfeld-Jakob disease or Gerstmann-Straussler-Scheinker disease.